Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma

Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma

BackgroundAntiangiogenic agents that specifically target vascular endothelial growth factor receptor (VEGFR), such as sunitinib, have been utilized as the standard therapy for metastatic clear cell renal cell carcinoma (ccRCC) patients. However, most patients eventually show no responses to the targ...

Full description

Bibliographic Details
Main Authors: Yuang Wei, Xinglin Chen, Xiaohan Ren, Bao Wang, Qian Zhang, Hengtao Bu, Jian Qian, Pengfei Shao
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Genetics
Subjects:
sunitinib resistance
drug resistance
antiangiogenic therapy
TKIs
clear cell renal cell carcinoma
human myxovirus resistance protein 2
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2021.680369/full

Internet

https://www.frontiersin.org/articles/10.3389/fgene.2021.680369/full

Similar Items